All In Biotech

Drug Trial Radar · NCT03853798

Extension Study of AG-348 in Adult Participants With Pyruvate Kinase Deficiency Previously Enrolled in AG-348-006 or AG348-C-007

An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies

Last checked: Nov 19, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

90

Actual

Start

Mar 21, 2019

Primary completion

Jul 3, 2024

Study completion Jul 3, 2024

Sponsor

Lead sponsor
Agios Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Feb 26, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multicenter, extension study to evaluate the long-term safety, tolerability, and efficacy of treatment with mitapivat in participants who were previously enrolled in Study AG348-C-006 or Study AG348-C-007.

Conditions

  • Pyruvate Kinase Deficiency

Interventions

  • MitapivatDrug

    Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. All Cohorts: Number of Participants With at Least One Treatment Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3Time frame: Up to 197 weeks
  2. All Cohorts: Number of Participants With TEAEs Leading to Dose Reduction, Treatment Interruption and Treatment DiscontinuationTime frame: Up to 197 weeks
  3. All Cohorts: Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters Reported as Grade Greater Than or Equal to (≥)3 TEAEsTime frame: Up to 197 weeks
  4. All Cohorts: Number of Participants With Clinically Significant Abnormalities in Vital Signs Measurements and Physical Examinations Reported as TEAEsTime frame: Up to 197 weeks
  5. All Cohorts: Number of Participants With Clinically Significant Abnormalities in Bone Mineral Density (BMD)Time frame: Up to 192 weeks
  6. All Cohorts: Change From Baseline in Adjusted Spine T-scoreTime frame: Baseline, Week 192
  7. All Cohorts: Change From Baseline in Adjusted Spine Z-scoreTime frame: Baseline, Week 192
  8. All Cohorts: Change From Baseline in Femoral Total T-scoreTime frame: Baseline, Week 192
  9. All Cohorts: Change From Baseline in Femoral Total Z-scoreTime frame: Baseline, Week 192
  10. All Cohorts: Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Parameters Reported as TEAEsTime frame: Up to 197 weeks

Locations

42 sites in 16 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • UCSF Benioff Children's Hospital, Oakland

    Oakland, California

  • Emory-Children's Center

    Atlanta, Georgia

  • Indiana Hemophilia & Thrombosis Center Inc.

    Indianapolis, Indiana

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Boston Children's Hospital

    Boston, Massachusetts

  • Wayne State University School of Medicine

    Detroit, Michigan

  • Duke University Medical Center

    Durham, North Carolina

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio

  • Houston Methodist Research Institute

    Houston, Texas

  • University of Utah

    Salt Lake City, Utah

  • Seattle Cancer Care Alliance

    Seattle, Washington

  • UNICAMP - Hemocentro

    São Paulo, Brazil

  • McMaster University

    Hamilton, Ontario, Canada

  • Herlev University Hospital

    Herlev, Denmark

  • CHU Hopitaux de Bordeaux - Hôpital Saint-André

    Bordeaux, France

  • CHU Hôpital Henri Mondor

    Créteil, France

  • Hospital La Timone

    Marseille, France

  • Institut Universitaire du Cancer de Toulouse - Oncopole

    Toulouse, France

  • Charite - UB - CVK - Medizinische Klinik

    Berlin, Germany

  • Universitätsklinik Würzburg

    Würzburg, Germany

  • St James's Hospital

    Dublin, Ireland

  • Ospedale Galliera

    Genova, Italy

  • Osp Maggiore Policlinico Milano

    Milan, Italy

  • AORN Cardarelli

    Naples, Italy

  • Università della Campania "Luigi Vanvitelli"

    Naples, Italy

  • Kyoto Katsura Hospital

    Kyoto, Japan

  • Kansai Medical University, Dep. of Pediatrics, Hirakata Hospital

    Osaka, Japan

  • Toho University Omori Medical Center

    Tokyo, Japan

  • Mie University Hospital

    Tsu, Mie-ken, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Van Creveldkliniek

    Utrecht, Netherlands

  • Yeungnam University Hospital

    Daegu, South Korea

  • Hospital. U. Vall d'Hebron

    Barcelona, Spain

  • Hospital Universitario La Paz

    Madrid, Spain

  • Htal Clínico Universitario Virgen de la Arrixaca.

    Murcia, Spain

  • Centre Hospitalier Universitaire Vaudois (CHUV)

    Vaud (Lausanne), Switzerland

  • Faculty of Medicine Siriraj Hospital

    Bangkok, Thailand

  • Hacettepe University Faculty of Medicine

    Ankara, Turkey (Türkiye)

  • Addenbrooke's Hospital

    Cambridge, United Kingdom

Showing 40 of 42 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.